Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action

Journal of Proteome Research

Volumn 10, Issue 12, 2011, Pages 5433-5443

  Xuan, Jiekun ^a,f   Pan, Guihua ^b   Qiu, Yunping ^c   Yang, Lun ^a   Su, Mingming ^d   Liu, Yumin ^a   Chen, Jian ^a   Feng, Guoyin ^b   Fang, Yiru ^b   Jia, Wei ^c   Xing, Qinghe ^a,e   He, Lin ^a,e,f  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI MENTAL HEALTH CENTER   (China)

^c UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

^d David H Murdock Research Institute   (United States)

^e FUDAN UNIVERSITY   (China)

^f Chinese Academy of Sciences   (China)

Author keywords

atypical antipsychotics; gas chromatography mass spectrometry; metabolomics; potential biomarkers; schizophrenia

Indexed keywords

ALLANTOIN; ATYPICAL ANTIPSYCHOTIC AGENT; BIOLOGICAL MARKER; CITRIC ACID; FATTY ACID; INOSITOL; NEUROTRANSMITTER; PALMITIC ACID; PHOSPHOLIPID; RISPERIDONE;

ADULT; ARTICLE; BIOSYNTHESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG MONITORING; FEMALE; GAS CHROMATOGRAPHY; HUMAN; MALE; MASS SPECTROMETRY; MENTAL DISEASE; METABOLITE; METABOLOMICS; MONOTHERAPY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; SERUM;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CITRIC ACID; ENERGY METABOLISM; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; METABOLIC NETWORKS AND PATHWAYS; METABOLOME; MIDDLE AGED; PALMITIC ACID; PRINCIPAL COMPONENT ANALYSIS; RISPERIDONE; SCHIZOPHRENIA; URIC ACID;

EID: 82755181967     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr2006796     Document Type: Article

References (65)

1. Sawa, A.; Snyder, S. H. Schizophrenia: diverse approaches to a complex disease Science 2002, 296 (5568) 692-695 (Pubitemid 34441987)
2. Buckley, P. F. Broad therapeutic uses of atypical antipsychotic medications Biol. Psychiatry 2001, 50 (11) 912-924 (Pubitemid 34020702)
3. Marder, S. R.; Meibach, R. C. Risperidone in the treatment of schizophrenia Am. J. Psychiatry 1994, 151 (6) 825-835
4. Stöber, G.; Ben-Shachar, D.; Cardon, M.; Falkai, P.; Fonteh, A. N.; Gawlik, M.; Glenthoj, B. Y.; Grunblatt, E.; Jablensky, A.; Kim, Y. K.; Kornhuber, J.; McNeil, T. F.; Muller, N.; Oranje, B.; Saito, T.; Saoud, M.; Schmitt, A.; Schwartz, M.; Thome, J.; Uzbekov, M.; Durany, N.; Riederer, P. Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers World J. Biol. Psychiatry 2009, 10 (2) 127-155
5. Thomas, E. A. Molecular profiling of antipsychotic drug function: convergent mechanisms in the pathology and treatment of psychiatric disorders Mol. Neurobiol. 2006, 34 (2) 109-128 (Pubitemid 46594649)
6. Nicholson, J. K. Global systems biology, personalized medicine and molecular epidemiology Mol. Syst. Biol. 2006, 2, 52
7. Gramolini, A. O.; Peterman, S. M.; Kislinger, T. Mass spectrometry-based proteomics: a useful tool for biomarker discovery? Clin. Pharmacol. Ther. 2008, 83 (5) 758-760 (Pubitemid 351559600)
8. Holmes, E.; Wilson, I. D.; Nicholson, J. K. Metabolic Phenotyping in Health and Disease Cell 2008, 134 (5) 714-717
9. Quinones, M. P.; Kaddurah-Daouk, R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases Neurobiol. Dis. 2009, 35 (2) 165-176
10. Holmes, E.; Tsang, T. M.; Huang, J. T.; Leweke, F. M.; Koethe, D.; Gerth, C. W.; Nolden, B. M.; Gross, S.; Schreiber, D.; Nicholson, J. K.; Bahn, S. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia PLoS Med. 2006, 3 (8) e327
11. Prabakaran, S.; Swatton, J. E.; Ryan, M. M.; Huffaker, S. J.; Huang, J. T.; Griffin, J. L.; Wayland, M.; Freeman, T.; Dudbridge, F.; Lilley, K. S.; Karp, N. A.; Hester, S.; Tkachev, D.; Mimmack, M. L.; Yolken, R. H.; Webster, M. J.; Torrey, E. F.; Bahn, S. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress Mol. Psychiatry 2004, 9 (7) 684-697; 643 (Pubitemid 38932173)
12. Yao, J. K.; Dougherty, G. G., Jr. ; Reddy, R. D.; Keshavan, M. S.; Montrose, D. M.; Matson, W. R.; Rozen, S.; Krishnan, R. R.; McEvoy, J.; Kaddurah-Daouk, R. Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia Mol. Psychiatry 2010, 15 (9) 938-953
13. Khaitovich, P.; Lockstone, H. E.; Wayland, M. T.; Tsang, T. M.; Jayatilaka, S. D.; Guo, A. J.; Zhou, J.; Somel, M.; Harris, L. W.; Holmes, E.; Pääbo, S.; Bahn, S. Metabolic changes in schizophrenia and human brain evolution Genome Biol. 2008, 9 (8) R124
14. Tsang, T. M.; Huang, J. T.; Holmes, E.; Bahn, S. Metabolic profiling of plasma from discordant schizophrenia twins: correlation between lipid signals and global functioning in female schizophrenia patients J. Proteome Res. 2006, 5 (4) 756-760
15. Li, H.; Xie, Z.; Lin, J.; Song, H.; Wang, Q.; Wang, K.; Su, M.; Qiu, Y.; Zhao, T.; Song, K.; Wang, X.; Zhou, M.; Liu, P.; Zhao, G.; Zhang, Q.; Jia, W. Transcriptomic and metabonomic profiling of obesity-prone and obesity-resistant rats under high fat diet J. Proteome Res. 2008, 7 (11) 4775-4783
16. Smith, C. A.; Want, E. J.; O'Maille, G.; Abagyan, R.; Siuzdak, G. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification Anal. Chem. 2006, 78 (3) 779-787 (Pubitemid 43228585)
17. Lundstedt, T.; Seifert, E.; Abramo, L.; Thelin, B.; Nyström, Å.; Pettersen, J.; Bergman, R. Experimental design and optimization Chemometr. Intell. Lab. 1998, 42 (1-2) 3-40 (Pubitemid 28440359)
18. Ben-Hur, A.; Ong, C. S.; Sonnenburg, S.; Schölkopf, B.; Rätsch, G. Support vector machines and kernels for computational biology PLoS Comput. Biol. 2008, 4 (10) e1000173
19. Stone, M. Cross validatory choice and assessment of statistical predictions J. R. Stat. Soc. Ser. B: Methodological 1974, 36 (2) 111-147
20. Chang, C. C.; Lin, C. J. LIBSVM: a library for support vector machines; 2001; Software available at http://www.csie.ntu.edu.tw/cjlin/libsvm.
21. Carey, V.; Redestig, H. ROC: utilities for ROC, with uarray focus; 2009; Software available at http://www.bioconductor.org.
22. Uchida, H.; Pollock, B. G.; Bies, R. R.; Mamo, D. C. Predicting age-specific dosing of antipsychotics Clin. Pharmacol. Ther. 2009, 86 (4) 360-362
23. van der Greef, J.; Davidov, E.; Verheij, E.; Vogels, J. T. W. E.; van der Heijden, R.; Adourian, A. S.; Oresic, M.; Marple, E. W.; Naylor, S. The role of metabolomics in systems biology, a new vision for drug discovery and development. In Metabolic Profiling: Its Role in Biomarker Discovery and Gene Function Analysis; Harrigan, G. G.; Goodacre, R., Eds.; Kluwer Academic Publishers: Boston, 2003; pp 170-198.
24. Clarke, D. D.; Sokoloff, L. Circulation and energy metabolism of the brain. In Basic Neurochemistry: Molecular, Cellular and Medical Aspects, 6 th ed.; Siegel, G. J.; Agranoff, B. W.; Albers, R. W.; Fisher, S. K., Eds.; Lippencott-Raven: Philadelphia, 1999; pp 637-669.
25. Verma, S. K.; Subramaniam, M.; Liew, A.; Poon, L. Y. Metabolic risk factors in drug-naive patients with first-episode psychosis J. Clin. Psychiatry 2009, 70 (7) 997-1000
26. Stone, W. S.; Faraone, S. V.; Su, J.; Tarbox, S. I.; Van Eerdewegh, P.; Tsuang, M. T. Evidence for linkage between regulatory enzymes in glycolysis and schizophrenia in a multiplex sample Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2004, 127B (1) 5-10 (Pubitemid 38542305)
27. Herberth, M.; Koethe, D.; Cheng, T. M.; Krzyszton, N. D.; Schoeffmann, S.; Guest, P. C.; Rahmoune, H.; Harris, L. W.; Kranaster, L.; Leweke, F. M.; Bahn, S. Impaired glycolytic response in peripheral blood mononuclear cells of first-onset antipsychotic-naive schizophrenia patients Mol. Psychiatry 2011, 16, 848-859
28. Ames, B. N.; Cathcart, R.; Schwiers, E.; Hochstein, P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis Proc. Natl. Acad. Sci. U.S.A. 1981, 78 (11) 6858-6862 (Pubitemid 12216861)
29. Dietrich, M.; Traber, M. G.; Jacques, P. F.; Cross, C. E.; Hu, Y.; Block, G. Does gamma-tocopherol play a role in the primary prevention of heart disease and cancer? A review J. Am. Coll. Nutr. 2006, 25 (4) 292-299 (Pubitemid 44414696)
30. Yao, J. K.; Keshavan, M. S. Antioxidants, Redox Signaling, and Pathophysiology in Schizophrenia: An Integrative View Antioxid. Redox. Signal. 2011, 15 (7) 2011-2035
31. Kaur, H.; Halliwell, B. Action of biologically-relevant oxidizing species upon uric acid. Identification of uric acid oxidation products Chem. Biol. Interact. 1990, 73 (2-3) 235-247 (Pubitemid 20097188)
32. Kand'ár, R.; Záková, P.; Muzáková, V. Monitoring of antioxidant properties of uric acid in humans for a consideration measuring of levels of allantoin in plasma by liquid chromatography Clin. Chim. Acta 2006, 365 (1-2) 249-256
33. Kand'ár, R.; Záková, P. Allantoin as a marker of oxidative stress in human erythrocytes Clin. Chem. Lab. Med. 2008, 46 (9) 1270-1274
34. Breier, A. Serotonin, schizophrenia and antipsychotic drug action Schizophr. Res. 1995, 14 (3) 187-202
35. Fernstrom, J. D.; Wurtman, R. J. Brain serotonin content: physiological dependence on plasma tryptophan levels Science 1971, 173 (992) 149-152
36. Manowitz, P.; Gilmour, D. G.; Racevskis, J. Low plasma tryptophan levels in recently hospitalized schizophrenics Biol. Psychiatry 1973, 6 (2) 109-118
37. Domino, E. F.; Krause, R. R. Free and bound serum tryptophan in drug-free normal controls and chronic schizophrenic patients Biol. Psychiatry 1974, 8 (3) 265-279
38. Meltzer, H. Y. The role of serotonin in antipsychotic drug action Neuropsychopharmacology 1999, 21 (2 Suppl) 106S-115S (Pubitemid 29396478)
39. Alfredsson, G.; Wiesel, F. A. Relationships between clinical effects and monoamine metabolites and amino acids in sulpiride-treated schizophrenic patients Psychopharmacology 1990, 101 (3) 324-331 (Pubitemid 20193369)
40. Fernstrom, J. D.; Fernstrom, M. H. Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain J. Nutr. 2007, 137 (6 Suppl 1) 1539S-1547S; discussion 1548S (Pubitemid 46855503)
41. Glazer, W. M. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality J. Clin. Psychiatry 2000, 61 (Suppl 3) 16-21 (Pubitemid 30155229)
42. Hertel, P.; Nomikos, G. G.; Iurlo, M.; Svensson, T. H. Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain Psychopharmacology 1996, 124 (1-2) 74-86 (Pubitemid 26112776)
43. Li, X. M.; Perry, K. W.; Wong, D. T.; Bymaster, F. P. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum Psychopharmacology 1998, 136 (2) 153-161 (Pubitemid 28137955)
44. Moffett, J. R.; Ross, B.; Arun, P.; Madhavarao, C. N.; Namboodiri, A. M. N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology Prog. Neurobiol. 2007, 81 (2) 89-131 (Pubitemid 46282272)
45. Middleton, F. A.; Mirnics, K.; Pierri, J. N.; Lewis, D. A.; Levitt, P. Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia J. Neurosci. 2002, 22 (7) 2718-2729 (Pubitemid 37465821)
46. Abbott, C.; Bustillo, J. What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update Curr. Opin. Psychiatry 2006, 19 (2) 135-139 (Pubitemid 44406123)
47. Patneau, D. K.; Mayer, M. L. Structure-activity relationships for amino acid transmitter candidates acting at N-methyl-D-aspartate and quisqualate receptors J. Neurosci. 1990, 10 (7) 2385-2399
48. Olney, J. W.; Farber, N. B. Glutamate receptor dysfunction and schizophrenia Arch. Gen. Psychiatry 1995, 52 (12) 998-1007
49. Tarazi, F. I.; Baldessarini, R. J.; Kula, N. S.; Zhang, K. Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment J. Pharmacol. Exp. Ther. 2003, 306 (3) 1145-1151 (Pubitemid 37025325)
50. Choi, Y. K.; Gardner, M. P.; Tarazi, F. I. Effects of risperidone on glutamate receptor subtypes in developing rat brain Eur. Neuropsychopharmacol. 2009, 19 (2) 77-84
51. Downes, C. P.; Macphee, C. H. myo-inositol metabolites as cellular signals Eur. J. Biochem. 1990, 193 (1) 1-18 (Pubitemid 20331603)
52. Berridge, M. J. Inositol trisphosphate and calcium signalling Nature 1993, 361 (6410) 315-325 (Pubitemid 23041621)
53. Kim, H.; McGrath, B. M.; Silverstone, P. H. A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (PI-cycle) to psychiatric disorders - focus on magnetic resonance spectroscopy (MRS) studies Hum. Psychopharmacol. 2005, 20 (5) 309-326 (Pubitemid 41093934)
54. Jope, R. S.; Song, L.; Grimes, C. A.; Pacheco, M. A.; Dilley, G. E.; Li, X.; Meltzer, H. Y.; Overholser, J. C.; Stockmeier, C. A. Selective increases in phosphoinositide signaling activity and G protein levels in postmortem brain from subjects with schizophrenia or alcohol dependence J. Neurochem. 1998, 70 (2) 763-771 (Pubitemid 28079367)
55. Skosnik, P. D.; Yao, J. K. From membrane phospholipid defects to altered neurotransmission: is arachidonic acid a nexus in the pathophysiology of schizophrenia? Prostaglandins Leukot Essent. Fatty Acids 2003, 69 (6) 367-384 (Pubitemid 37464046)
56. Fenton, W. S.; Hibbeln, J.; Knable, M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia Biol. Psychiatry 2000, 47 (1) 8-21 (Pubitemid 30016075)
57. Lieberman, J. A.; Bymaster, F. P.; Meltzer, H. Y.; Deutch, A. Y.; Duncan, G. E.; Marx, C. E.; Aprille, J. R.; Dwyer, D. S.; Li, X. M.; Mahadik, S. P.; Duman, R. S.; Porter, J. H.; Modica-Napolitano, J. S.; Newton, S. S.; Csernansky, J. G. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection Pharmacol. Rev. 2008, 60 (3) 358-403
58. Polymeropoulos, M. H.; Licamele, L.; Volpi, S.; Mack, K.; Mitkus, S. N.; Carstea, E. D.; Getoor, L.; Thompson, A.; Lavedan, C. Common effect of antipsychotics on the biosynthesis and regulation of fatty acids and cholesterol supports a key role of lipid homeostasis in schizophrenia Schizophr. Res. 2009, 108 (1-3) 134-142
59. Newcomer, J. W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review C.N.S. Drugs 2005, 19 (Suppl 1) 1-93 (Pubitemid 40677047)
60. Vestri, H. S.; Maianu, L.; Moellering, D. R.; Garvey, W. T. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis Neuropsychopharmacology 2007, 32 (4) 765-772 (Pubitemid 46426168)
61. Lauressergues, E.; Staels, B.; Valeille, K.; Majd, Z.; Hum, D. W.; Duriez, P.; Cussac, D. Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes Naunyn Schmiedebergs Arch. Pharmacol. 2010, 381 (5) 427-439
62. Lauressergues, E.; Martin, F.; Helleboid, A.; Bouchaert, E.; Cussac, D.; Bordet, R.; Hum, D.; Luc, G.; Majd, Z.; Staels, B.; Duriez, P. Overweight induced by chronic risperidone exposure is correlated with overexpression of the SREBP-1c and FAS genes in mouse liver Naunyn Schmiedebergs Arch. Pharmacol. 2011, 383 (4) 423-436
63. Prentki, M.; Madiraju, S. R. Glycerolipid Metabolism and Signaling in Health and Disease Endocr. Rev. 2008, 29 (6) 647-676
64. Hunter, S. J.; Garvey, W. T. Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction, and the glucose transport effector system Am. J. Med. 1998, 105 (4) 331-345 (Pubitemid 28487541)
65. Samuel, V. T.; Petersen, K. F.; Shulman, G. I. Lipid-induced insulin resistance: unravelling the mechanism Lancet 2010, 375 (9733) 2267-2277